Bavarian Nordic to raise €387m to fund GSK vaccines purchase
by Aidan Gregory
March 06, 2020 03:45 PM
Danish pharmaceuticals company Bavarian Nordic has announced an Nkr2.8bn (€378m) rights issue to fund its acquisition of GlaxoSmithKline’s commercial and manufacturing rights to Rabipur, a treatment for rabies, and Encepur, a vaccine against tick-borne encephalitis.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.